Skip to main content

Vertex Pharmaceuticals Incorpor (VRTX) Stock

Vertex Pharmaceuticals Incorpor Stock Details, Movements and Public Alerts

Stock Details

Vertex Pharmaceuticals Incorpor (VRTX), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $525.00. Over the past 52 weeks, it has ranged between $403.16 and $560.25. This places the current price at 93.7% of its 52-week high and 30.2% above its 52-week low. Recent trading volume was recorded at 832,628. The 14-day Relative Strength Index (RSI) stands at 55.07, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $522.71 by 0.44%. Similarly, it is above its 200-day moving average of $477.37 by 9.98%. The MACD histogram is 3.42, indicating bullish momentum (MACD Line: 0.74, Signal Line: -2.68). The International Securities Identification Number (ISIN) for this stock is US92532F1003. There is currently 1 active alert set for VRTX by users.

52-Week Range

$560.25 - $403.16

-6.29% from high · +30.22% from low

Avg Daily Volume

1,230,935

20-day average

100-day avg: 1,368,972

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

30.51

Above market average

Forward P/E

25.66

Earnings expected to grow

PEG Ratio

2.10

Potentially overvalued

Price to Book

6.56

EV/EBITDA

24.88

EPS (TTM)

$17.17

Price to Sales

10.54

Beta

0.28

Less volatile than market

Q:How is VRTX valued relative to its earnings and growth?
Vertex Pharmaceuticals Incorpor trades at a P/E ratio of 30.51, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 25.66 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 2.10 indicates a premium valuation even accounting for growth.
Q:What is VRTX's risk profile compared to the market?
With a beta of 0.28, Vertex Pharmaceuticals Incorpor is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 6.56 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

35.00%

Operating Margin

38.05%

EBITDA

$5.10B

Return on Equity

23.54%

Return on Assets

11.93%

Revenue Growth (YoY)

12.50%

Earnings Growth (YoY)

8.00%

Q:How profitable and efficient is VRTX's business model?
Vertex Pharmaceuticals Incorpor achieves a profit margin of 35.00%, meaning it retains $35.00 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 38.05% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 23.54% and ROA at 11.93%, the company generates strong returns on invested capital.
Q:What are VRTX's recent growth trends?
Vertex Pharmaceuticals Incorpor's revenue grew by 12.50% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 8.00% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$132.7B

Revenue (TTM)

$12.59B

Revenue/Share (TTM)

$49.51

Shares Outstanding

253.30M

Book Value/Share

$79.92

Asset Type

EQUITY

Q:What is VRTX's market capitalization and position?
Vertex Pharmaceuticals Incorpor has a market capitalization of $132.7B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 253.30M shares outstanding, the company's ownership is relatively concentrated. As a major player in the Biotechnology industry, it competes with other firms in this sector.
Q:How does VRTX's price compare to its book value?
Vertex Pharmaceuticals Incorpor's book value per share is $79.92, while the current stock price is $525.00, resulting in a price-to-book (P/B) ratio of 6.57. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$571.46

8.85% upside potential

Analyst Recommendations

Strong Buy

4

Buy

19

Hold

6

Sell

1

Strong Sell

1

Q:How reliable are analyst predictions for VRTX?
31 analysts cover VRTX with 74% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $571.46 implies 8.9% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on VRTX?
Current analyst recommendations:4 Strong Buy, 19 Buy, 6 Hold, 1 Sell, 1 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 24, 2026, 02:03 AM

Technical Indicators

RSI (14-day)

55.07

Neutral

50-Day Moving Average

$522.71

0.44% above MA-50

200-Day Moving Average

$477.37

9.98% above MA-200

MACD Line

0.74

MACD Signal

-2.68

MACD Histogram

3.42

Bullish

Q:What does VRTX's RSI value tell investors?
The RSI (Relative Strength Index) for VRTX is currently 55.07, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret VRTX's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.74 above the signal line at -2.68, with histogram at 3.42. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($522.71) is above the 200-day MA ($477.37), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Oct 24, 2026, 01:20 AM

Active Alerts

Alert Condition
Price decreases by
Threshold
20%
Created
Apr 28, 2026, 07:26 PM

Stay Ahead of the Market with Vertex Pharmaceuticals Incorpor Alerts

Set up price alerts for Vertex Pharmaceuticals Incorpor and get notified instantly when the price hits your target. Never miss an important price movement again.